Cargando…

ABT-263 exerts a protective effect on upper urinary tract damage by alleviating neurogenic bladder fibrosis

This study investigated the mechanism of action of ABT-263 in the treatment of neurogenic bladder fibrosis (NBF)and its protective effects against upper urinary tract damage (UUTD). Sixty 12-week-old Sprague-Dawley (SD) rats were randomly divided into sham, sham + ABT-263 (50 mg/kg), NBF, NBF + ABT-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen, Yibo, Wu, Junwei, Pu, Qingsong, He, Xiangfei, Wang, Junkui, Feng, Jinjin, Zhang, Yanping, Si, Feng, Wen, Jian Guo, Yang, Jinghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167888/ https://www.ncbi.nlm.nih.gov/pubmed/37154092 http://dx.doi.org/10.1080/0886022X.2023.2194440

Ejemplares similares

Activation of the TGF-β1/Smads/α-SMA pathway is related to histological and functional changes in children with neurogenic bladder
por: Yang, Xinghuan, et al.
Publicado: (2022)

ABT-263 Reduces Hypertrophic Scars by Targeting Apoptosis of Myofibroblasts
por: Yang, Xiaolan, et al.
Publicado: (2021)

A nomogram for predicting upper urinary tract damage risk in children with neurogenic bladder
por: Li, Qi, et al.
Publicado: (2022)

Efficient Elimination of Cancer Cells by Deoxyglucose-ABT-263/737 Combination Therapy
por: Yamaguchi, Ryuji, et al.
Publicado: (2011)

Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells
por: Yu, Rui, et al.
Publicado: (2021)

ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer
por: Chen, Qiongrong, et al.
Publicado: (2015)

KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib
por: Wang, Guihua, et al.
Publicado: (2019)

Mcl-1 levels need not be lowered for cells to be sensitized for ABT-263/737-induced apoptosis
por: Yamaguchi, R, et al.
Publicado: (2011)

Single Agent and Synergistic Activity of Maritoclax with ABT-263 in Nasopharyngeal Carcinoma (NPC) Cell Lines
por: Xiang, Benedict Lian Shi, et al.
Publicado: (2020)

Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199
por: García, Carolina Paola, et al.
Publicado: (2016)

ABT-263 Enhances Sensitivity to Metformin and 2-Deoxyglucose in Pediatric Glioma by Promoting Apoptotic Cell Death
por: Levesley, Jane, et al.
Publicado: (2013)

Data on the DNA damaging and mutagenic potential of the BH3-mimetics ABT-263/Navitoclax and TW-37
por: Green, Maja M., et al.
Publicado: (2016)

Combining Paclitaxel with ABT-263 Has a Synergistic Effect on Paclitaxel Resistant Prostate Cancer Cells
por: Wang, Chihuei, et al.
Publicado: (2015)

Navitoclax (ABT263) reduces inflammation and promotes chondrogenic phenotype by clearing senescent osteoarthritic chondrocytes in osteoarthritis
por: Yang, Hao, et al.
Publicado: (2020)

ABT-263 enhanced bacterial phagocytosis of macrophages in aged mouse through Beclin-1-dependent autophagy
por: Zhang, Yu, et al.
Publicado: (2021)

Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment
por: Britt, Erin L., et al.
Publicado: (2019)

BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation
por: Zhan, Yihong, et al.
Publicado: (2019)

The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice
por: Sharma, Anuj K., et al.
Publicado: (2020)

Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
por: Ritter, Violetta, et al.
Publicado: (2021)

Inhibition of antiapoptotic BCL-2 proteins with ABT-263 induces fibroblast apoptosis, reversing persistent pulmonary fibrosis
por: Cooley, Joseph C., et al.
Publicado: (2023)

JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer
por: Wang, Huogang, et al.
Publicado: (2017)

Intracellular levels of reactive oxygen species correlate with ABT‐263 sensitivity in non‐small‐cell lung cancer cells
por: Ohgino, Keiko, et al.
Publicado: (2020)

Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
por: Ritter, Violetta, et al.
Publicado: (2022)

Clearance of senescent cells with ABT-263 improves biological functions of synovial mesenchymal stem cells from osteoarthritis patients
por: Miura, Yugo, et al.
Publicado: (2022)

EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263
por: Abdelgawad, Ibrahim Y., et al.
Publicado: (2022)

Treatment of advanced atherosclerotic mice with the senolytic agent ABT-263 is associated with reduced indices of plaque stability and increased mortality
por: Karnewar, Santosh, et al.
Publicado: (2023)

Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice
por: Kakkola, L, et al.
Publicado: (2013)

Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells
por: Airiau, Kelly, et al.
Publicado: (2015)

Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐X(L)–BAX interaction
por: Saleh, Tareq, et al.
Publicado: (2020)

Effects and Related Mechanisms of the Senolytic Agent ABT-263 on the Survival of Irradiated A549 and Ca9-22 Cancer Cells
por: Sato, Kota, et al.
Publicado: (2021)

Taking Advantage of the Senescence-Promoting Effect of Olaparib after X-ray and Proton Irradiation Using the Senolytic Drug, ABT-263
por: Huart, Camille, et al.
Publicado: (2022)

The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells
por: Wang, Bin, et al.
Publicado: (2014)

Inhibition of KIT-Glycosylation by 2-Deoxyglucose Abrogates KIT-Signaling and Combination with ABT-263 Synergistically Induces Apoptosis in Gastrointestinal Stromal Tumor
por: Mühlenberg, Thomas, et al.
Publicado: (2015)

Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines
por: Lian, Benedict Shi Xiang, et al.
Publicado: (2018)

TXNIP induces growth arrest and enhances ABT263‐induced apoptosis in mixed‐lineage leukemia‐rearranged acute myeloid leukemia cells
por: Noura, Mina, et al.
Publicado: (2020)

Neurogenic Bladder
por: Dorsher, Peter T., et al.
Publicado: (2012)

Synergism of a novel MCL-1 downregulator, acriflavine, with navitoclax (ABT-263) in triple-negative breast cancer, lung adenocarcinoma and glioblastoma multiforme
por: Lee, Anbok, et al.
Publicado: (2021)

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
por: Leverson, J D, et al.
Publicado: (2015)

Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines
por: Lam, Lloyd T, et al.
Publicado: (2015)

The Bcl-2/Bcl-xL Inhibitor ABT-263 Attenuates Retinal Degeneration by Selectively Inducing Apoptosis in Senescent Retinal Pigment Epithelial Cells
por: Ryu, Wonseon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s6eqem4bb3ceif07ke2cf9t92l